A retrospective study to assess real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma
Latest Information Update: 24 Jul 2020
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 24 Jul 2020 New trial record